中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

100 records (took 0.03 seconds)

    HERPES SIMPLEX VIRUS US3 AND ICP4 AS INHIBITORS OF APOPTOSIS
    3.
    发明申请
    HERPES SIMPLEX VIRUS US3 AND ICP4 AS INHIBITORS OF APOPTOSIS 审中-公开
    HERPES SIMPLEX VIRUS US3和ICP4作为APOPTOSIS的抑制剂

    公开(公告)号：WO9846637A3

    公开(公告)日：1999-01-28

    申请号：PCT/US9807573

    申请日：1998-04-16

    Applicant: ARCH DEV CORP ,  LEOPARDI ROSARIO ,  ROIZMAN BERNARD

    Inventor： LEOPARDI ROSARIO ,  ROIZMAN BERNARD

    IPC: A61K38/00 ,  C07K14/035 ,  C12N5/02 ,  C07K14/00

    CPC classification number: C07K14/005 ,  A61K38/00 ,  C12N2710/16622

    Abstract: The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that have transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an α4 gene, methods for inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections. Further, the present invention discloses that the HSV-1 mutant lacking the α4 gene, has a secondary mutation in the gene US3 specifying a protein kinase. Thus a functional US3, a viral gene encoding a protein kinase known to phosphorylate serine/threonine within a specific arginine rich consensus sequence, is required in order to block apoptosis. Also disclosed are methods for inhibition of apoptosis using US3 or an US3 encoding gene, methods for inhibiting US3's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.

    9.
    发明专利
    未知

    公开(公告)号：DK0675962T3

    公开(公告)日：2003-04-07

    申请号：DK94905494

    申请日：1993-12-22

    Applicant: ARCH DEV CORP

    Inventor： ROIZMAN BERNARD

    IPC: C07K14/05 ,  C07K14/77 ,  C12N15/85 ,  C12N15/869 ,  C12N15/86 ,  C12N15/12 ,  C12N15/38

    Abstract: The present invention relates to synthetic herpes simplex virus (HSV) promoters which are constructed by operatively linking the 5' nontranscribed domain of an HSV alpha gene to a fragment containing the transcription initiation site and the 5' transcribed noncoding region from an HSV gamma gene. Synthetic promoters of the invention that are operatively linked to heterologous genes, inserted into HSV genomes and used to generate live virus are useful for expressing polypeptides encoded by the heterologous genes in appropriate host cells. The synthetic promoters direct transcription of the heterologous genes constitutively throughout the reproductive cycle of the virus at a high cumulative level. The recombinant viruses of the invention can also be used as vaccines to present polypeptides against which a host will mount an immune response.

    10.
    发明专利
    未知

    公开(公告)号：DK0675961T3

    公开(公告)日：2003-03-24

    申请号：DK93907093

    申请日：1993-02-26

    Applicant: ARCH DEV CORP

    Inventor： ROIZMAN BERNARD ,  CHOU JOANY

    IPC: C12N15/09 ,  A61K31/70 ,  A61K35/30 ,  A61K38/00 ,  A61K38/16 ,  A61K39/245 ,  A61K48/00 ,  A61P25/00 ,  A61P31/12 ,  A61P35/00 ,  C07H21/04 ,  C07K14/035 ,  C12N15/38 ,  C12N15/869 ,  G01N33/50 ,  A61K37/02 ,  C07K13/00 ,  C12N15/86

    Abstract: The present invention relates to methods of treatment of programmed cell death (apoptosis) through the use of the HSV-1 gene gamma134.5 or the product of its expression, ICP34.5. The gene and its expression have been demonstrated to be required for HSV-1 neurovirulence, and in particular, to act as an inhibitor of neuronal programmed cell death which allows for viral replication. Use of the gene therapy, or the protein itself, can be expected to result in inhibition of programmed cell death in various neurodegenerative diseases. This invention also relates to novel vectors for gene therapy, including modified herpes virus. Methods are presented for conducting assays for substances capable of mimicing, potentiating or inhibiting the expression of gamma134.5 or the activity of ICP34.5. Also, methods are disclosed for the treatment of tumorogenic diseases, including cancer, and for treatment of herpes and other viral infections using inhibitors of gamma134.5 expression or ICP34.5 activity.

Patent Agency Ranking